Chronic Hepatitis C : Optipeg-A, alone or in combination with Ribavirin, is indicated for the treatment of aadults with chronic hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Chronic Hepatitis B ... Read more Chronic Hepatitis C : Optipeg-A, alone or in combination with Ribavirin, is indicated for the treatment of aadults with chronic hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Chronic Hepatitis B : Optipeg-A, is indicated for the treatment of adult patients with HBeAg positive and HBeAg negative chronic hepatitis B infection who have compensated liver disease and evidence of viral replication and liver inflammation.
Peginterferon alfa-2a, is a covalent conjugate of recombinant alfa-2a interferon with a single branched bis-monomethoxy polyethylene glycol chain. The Peginterferon alfa-2a moiety is linked at a single site to the interferon alfa moiety via a stable amide bond to lysine. Peginterferon alfa-2a has an approximate molecular weight of 60,000 daltons. Interferon alfa-2a is produced using recombinant DNA technology in which a cloned human leukocyte interferon gene is inserted into and expressed in Escherichia coli.
Chronic hepatitis C : The recommended dose of Peg interferon is 180 mcg once weekly for 48 weeks by subcutaneous administration on abdomen or thigh Chronic hepatitis B : The recommended dose of Peg interferon is 180 mcg once weekly for 48 weeks by subcutaneous administration on abdomen or thigh Hepatitis C Genotype 1 & 4: Pegylated Interferon alfa-2a Monotherapy: 180 mcg once weekly for 48 weeks Pegylated Interferon alfa-2a dual therapy: 180 mcg once weekly for 48 weeks; Celbarin: <75 kg= (400+0+600) mg, >75 kg= (600+0+600) mg. Hepatitis C Genotype 2 & 3: Pegylated Interferon alfa-2a Monotherapy: 180 mcg once weekly for 48 weeks Pegylated Interferon alfa-2a dual therapy: 180 mcg once weekly for 24 weeks; Celbarin: (400+0+400) mg. Pediatric Use : The safety and effectiveness of Pegferon®, alone or in combination with Ribavirin in patients below the age of 5 years have not been established.
Always consult a registered doctor before taking any medicine. This information is for general knowledge only.
Depression, suicide, relapse of drug abuse and bacterial infection Flu like symptoms: Fatigue, pyrexia, Gastrointestinal: Nausea/Vomiting, diarrhea, abdominal pain Metabolic and Nutritional: Anorexia Musculoskeletal: Myalgia, arthralgia Neurological: Headache, dizziness, insomnia Psychiatric reactions: Irritability, anxiety Injection site reaction, skin problems, hair loss Endocrine: Hypothyroidism
Hypersensitivity to any component of the product Autoimmune hepatitis Hepatic decompensation in cirrhotic patients before or during treatment Hepatic decompensation with Child-Pugh score greater than or equal to 6 in cirrhotic CHC patients co infected with HIV during or before treatment Neonate or infants.
Drugs metabolized by CYP1A2: monitor for increased serum levels of theophylline and adjust dose accordingly Methadone: monitor for signs and symptoms of methadone toxicity Nucleoside analogues: closely monitor for toxicities and dose reduce or discontinue Optipeg-A alfa 2a/ Ribavirin or both should event worsen Zidovudine: monitor for worsening neutropenia and/or anemia with peginterferon alfa/rifavirin Azathioprine.
Patients who have failed alpha interferon treatment with or without ribavirin Liver or other organ transplant recipients Hepatitis B patients coinfected with HCV or HIV Hepatitis C patients coinfected with HBV or coinfected with HIV with a CD4+ cell count < 100 cells/µL Caution should be exercised in initiating treatment in any patient with baseline risk of severe anemia